As a leading radiopharmaceutical manufacturer in Australia and New Zealand, our mission at Cyclotek is to improve patient outcomes with accessible targeted radiopharmaceuticals. Our novel PET-tracers provide patient-specific insights into their disease state, providing earlier diagnosis, more accurate assessment of disease extent and improved treatment planning and monitoring. Cyclotek has a strong history of undertaking product development and technology transfers to support clinical trials and investigator-sponsored studies. Cyclotek is at the forefront of validating new molecular targeted radiopharmaceuticals for the Australian and New Zealand market. Our infrastructure and personnel are designed and trained to enable these CDMO activities.
The University of Melbourne’s Bio21 Molecular Science and Biotechnology Institute (Bio21 Institute) is a multidisciplinary research centre specialising in the molecular life sciences. Accommodating more than 800 research scientists, students and industry tenants, the Bio21 Institute is one of the largest biotechnology research centres in Australia. The Bio21 Institute seeks to improve health through innovation in biotechnology and related areas, driven by collaborative research and dynamic interactions with industry.
[contact-form-7 id=”714″ title=”Update Form”]